Moxilubant (CGS-25019C,LTB-019) is an orally active BLT1 antagonist which inhibits LTB4 signaling with a potency of 2-4 nM. Moxilubant can be used for cancer research[1].
Molecular Weight:
455.59
Purity:
99.83
CAS Number:
[146978-48-5]
Formula:
C26H37N3O4
Target:
Leukotriene Receptor
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted